DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis

被引:26
作者
Ji, Yan-Mei [1 ]
Zhou, Xue-Feng [2 ]
Zhang, Jun [3 ]
Zheng, Xiang [1 ]
Li, Sheng-Bao [4 ]
Wei, Zhi-Qiang [5 ]
Liu, Tao [4 ]
Cheng, Dong-Liang [3 ]
Liu, Ping [6 ]
Song, Kuncheng [7 ]
Tan, Tao [7 ]
Zhu, Hua [7 ]
Guo, Jia-Long [3 ]
机构
[1] Hubei Univ Med, Taihe Hosp, Dept Intens Care Unit, Shiyan, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Thorac & Cardiovasc Surg, Wuhan 430072, Peoples R China
[3] Hubei Univ Med, Taihe Hosp, Dept Cardiothorac Surg, Shiyan, Peoples R China
[4] Hubei Univ Med, Taihe Hosp, Dept Gastroenterol, Shiyan, Peoples R China
[5] Hubei Univ Med, Taihe Hosp, Inst Biomed Res, Shiyan, Peoples R China
[6] Hubei Univ Med, Taihe Hosp, Dept Pathol, Shiyan, Peoples R China
[7] Ohio State Univ, Dept Surg, Wexner Med Ctr, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
关键词
DEPTOR; mTOR; esophageal squamous cell carcinoma; proliferation; BREAST-CANCER CELLS; PI3K/AKT/MTOR PATHWAY; MULTIPLE-MYELOMA; MTOR INHIBITORS; GASTRIC-CANCER; BETA-TRCP; EXPRESSION; RAPAMYCIN; THERAPY; TARGET;
D O I
10.18632/oncotarget.7420
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As a naturally occurring inhibitor of mTOR, accumulated evidence has suggested that DEPTOR plays a pivotal role in suppressing the progression of human malignances. However, the function of DEPTOR in the development of esophageal squamous cell carcinoma (ESCC) is still unclear. Here we report that the expression of DEPTOR is significantly reduced in tumor tissues derived from human patients with ESCC, and the downregulation of DEPTOR predicts a poor prognosis of ESCC patients. In addition, we found that the expression of DEPTOR negatively regulates the tumorigenic activities of ESCC cell lines (KYSE150, KYSE510 and KYSE190). Furthermore, ectopic DEPTOR expression caused a significant suppression of the cellular proliferation, migration and invasion of KYSE150 cells, which has the lowest expression level of DEPTOR in the three cell lines. Meanwhile, CRISPR/Cas9 mediated knockout of DEPTOR in KYSE510 cells significantly promoted cellular proliferation, migration and invasion. In addition, in vivo assays further revealed that tumor growth was significantly inhibited in xenografts with ectopic DEPTOR expression as compared to untreated KYSE150 cells, and was markedly enhanced in DEPTOR knockout KYSE-510 cells. Biochemical studies revealed that overexpression of DEPTOR led to the suppression of AKT/mTOR pathway as evidenced by reduced phosphorylation of AKT, mTOR and downstream SGK1, indicating DEPTOR might control the progression of ESCC through AKT/mTOR signaling pathway. Thus, these findings, for the first time, demonstrated that DEPTOR inhibits the tumorigenesis of ESCC cells and might serve as a potential therapeutic target or prognostic marker for human patients with ESCC.
引用
收藏
页码:14188 / 14198
页数:11
相关论文
共 36 条
[1]   mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? [J].
Boone, J. ;
Ten Kate, F. J. W. ;
Offerhaus, G. J. A. ;
van Diest, P. J. ;
Rinkes, I. H. M. Borel ;
van Hillegersberg, R. .
JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (08) :909-913
[2]   High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients [J].
Carrasco, DR ;
Tonon, G ;
Huang, YS ;
Zhang, YY ;
Sinha, R ;
Bin, F ;
Stewart, JP ;
Zhan, FG ;
Khatry, D ;
Protopopova, M ;
Protopopov, A ;
Sukhdeo, K ;
Hanamura, I ;
Stephens, O ;
Barlogie, B ;
Anderson, KC ;
Chin, L ;
Shaughnessy, JD ;
Brennan, C ;
DePinho, RA .
CANCER CELL, 2006, 9 (04) :313-325
[3]   Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway [J].
Corominas-Faja, Bruna ;
Cufi, Silvia ;
Oliveras-Ferraros, Cristina ;
Cuyas, Elisabet ;
Lopez-Bonet, Eugeni ;
Lupu, Ruth ;
Alarcon, Tomas ;
Vellon, Luciano ;
Manuel Iglesias, Juan ;
Leis, Olatz ;
Martin, Angel G. ;
Vazquez-Martin, Alejandro ;
Menendez, Javier A. .
CELL CYCLE, 2013, 12 (18) :3109-3124
[4]   mToR signaling and drug development in cancer [J].
Dancey, Janet .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (04) :209-219
[5]   mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR [J].
Duan, Shanshan ;
Skaar, Jeffrey R. ;
Kuchay, Shafi ;
Toschi, Alfredo ;
Kanarek, Naama ;
Ben-Neriah, Yinon ;
Pagano, Michele .
MOLECULAR CELL, 2011, 44 (02) :317-324
[6]   mTOR and cancer: many loops in one pathway [J].
Efeyan, Alejo ;
Sabatini, David M. .
CURRENT OPINION IN CELL BIOLOGY, 2010, 22 (02) :169-176
[7]   Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas [J].
Fang, MZ ;
Liu, CG ;
Song, YL ;
Yang, GY ;
Nie, Y ;
Liao, J ;
Zhao, X ;
Shimada, Y ;
Wang, LD ;
Yang, CS .
CARCINOGENESIS, 2004, 25 (06) :865-871
[8]   Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 [J].
Feldman, Morris E. ;
Apsel, Beth ;
Uotila, Aino ;
Loewith, Robbie ;
Knight, Zachary A. ;
Ruggero, Davide ;
Shokat, Kevan M. .
PLOS BIOLOGY, 2009, 7 (02) :371-383
[9]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[10]   The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma [J].
Gera, Joseph ;
Lichtenstein, Alan .
LEUKEMIA & LYMPHOMA, 2011, 52 (10) :1857-1866